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Abstract
There is a need for an effective and safe emetic agent that dog owners could easily administer to their dogs 
following veterinary advice in cases of potential poisoning. As a response to this need, a randomised, double-
blind, multi-site, clinical field study was performed to assess the efficacy, safety and usability of ropinirole 
eye drops to induce vomiting in dogs. Ropinirole (target dose 3.75 mg/m2) was applied to eyes of 100 dogs, 
and 32 dogs received placebo. The drug was administered by the dog owner at a veterinary clinic under the 
supervision of a veterinarian and led to vomition in 95% of the ropinirole-treated dogs within 30 min. The 
median time to first vomit was 10 min (range: 3–37 min). None of the dogs receiving placebo vomited in this 
time period. All owners were able to administer the product and 96% of them assessed the administration to 
be very easy or easy, which was confirmed by the observing veterinarian. Some ocular signs were seen both 
with ropinirole and placebo, hyperaemia being the most common. All observed signs were transient and in 
most cases mild. Ropinirole eye drops provided an effective, safe and reliable means to induce emesis in dogs.
Introduction
Induction of emesis in dogs is accepted as the first line of 
action for initial decontamination following ingestion 
of potentially toxic substances or other unwanted 
material, unless contraindicated. Contraindications 
for emesis induction include situations when the 
animal is depressed neurologically or the material 
ingested is corrosive or volatile.1 Vomiting can be 
induced by a number of chemicals acting centrally 
and/or peripherally to trigger the vomiting response.2 
For drugs the most direct and rapid way to initiate 
the vomiting response is via stimulating the 
chemoreceptor trigger zone (CTZ) in the brain stem. 
The CTZ is outside the blood–brain barrier and is rich 
in dopamine D2-type receptors.3 4 Drugs that activate 
D2-type receptors in CTZ are potent emetogens in 
several species, including dogs.5–7
Apomorphine is commonly used by veterinarians to 
induce emesis in dogs, but it is not licensed for animal 
use in the USA and is licensed only for administration 
by parenteral injection in Europe. Apomorphine 
induces vomiting by stimulating dopamine receptors in 
the CTZ. It is a non-selective dopamine receptor agonist 
that activates not only various dopamine receptor 
subtypes but also other classes of receptors activated 
by structurally related amine neurotransmitters, 
including a number of 5-hydroxytryptamine receptors 
and alpha-adrenoceptor subtypes.8 Apomorphine also 
stimulates µ-opioid receptors. As a consequence of the 
non-selectivity, the drug can have a number of side 
effects and at high doses inhibit vomiting through its 
opioid effects.9 This means that if vomiting does not 
occur after the first apomorphine injection, the repeated 
dosing is not likely to succeed. The side effects of 
apomorphine include prolonged vomiting, tachycardia 
and lethargy.10 11
Dog owners commonly use various substances 
such as hydrogen peroxide, table salt, ipecac syrup 
and liquid dishwashing detergent to induce emesis 
in their dog. The home remedies have limitations 
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including difficulty in administration, inappropriate 
dosing, lack of consistent efficacy and undesirable side 
effects.1 11 12 Currently, there is no authorised product 
available that could be easily and safely administered 
by the owner in case of emergencies, where the risk–
benefit assessment (undertaken by consultation with a 
veterinary professional) is in favour of inducing emesis 
at home. This would save valuable time, expediting 
gastric evacuation in a dog that has consumed a toxic 
substance.
Ropinirole is a full dopamine agonist with high 
selectivity for dopamine D2-type receptors,13 which 
mediate induction of emesis very readily in the dog.5 
Therefore, ropinirole was chosen as an active ingredient 
for a new emetic agent for use in dogs. As ropinirole is 
a dopamine D2 agonist, similar side effects including 
tachycardia as with apomorphine are to be expected.14 
However, due to the selective pharmacology of 
ropinirole, the number of unwanted effects is expected 
to be limited and those effects can be reversed with 
an antidote, such as dopamine receptor antagonist 
metoclopramide. Furthermore, the selectivity may also 
allow repeated administration of ropinirole to increase 
the vomiting inducing effect.
Other properties for the ‘ideal emetic agent’ include 
rapid onset of effect and short duration of action and 
it was hypothesised that ropinirole could fulfil these 
criteria. A novel ocular administration route of ropinirole 
was chosen to allow non-invasive administration while 
providing a fast and reliable absorption bypassing 
the gastrointestinal tract. Small-scale pilot clinical 
and pharmacokinetic studies were undertaken to 
determine the appropriate dose required by this route to 
reliably induce emesis (data on file, Orion Pharma). In 
addition, standalone cardiovascular safety studies were 
performed to verify cardiovascular safety of ropinirole in 
dogs (data on file, Orion Pharma). The aim of the study 
described in this paper was to confirm the efficacy and 
safety of ropinirole to induce emesis, and the usability 
of the product, when trialled by owners administering 
the eye drops to their dogs.
Materials and methods
Study design
The randomised, double-blind, placebo-controlled, 
parallel-group, clinical field study was carried out 
over a 10-week period between October and December 
2015 at six veterinary clinics in the USA. The study was 
conducted in compliance with the principles of Good 
Clinical Practice and subjected to internal ethical review 
at Orion Pharma. Protocol was also submitted for review 
to the US Food and Drug Administration (FDA) and 
concurrence was received prior to the study. Informed 
consent was obtained from the owners before enrolling 
their dog in the study. The welfare, treatment and care 
of the study animals were ensured by the investigator 
veterinarians.
Selection of animals
Client-owned male and female dogs of any breed and age 
were enrolled in this study. Dogs were recruited from the 
patient population of the clinic based on an earlier visit 
to the clinic, an owner interview and/or medical records. 
The owners were offered an incentive to participate in 
the study. To be eligible for the study, the dogs had to 
have a body weight of at least 1.8 kg to meet the target 
dose range if one drop was administered. The dogs had 
to be healthy or were allowed to have a mild systemic 
disease (status ASA I or II according to American Society 
of Anesthesiologists classification15 as adopted from 
human medicine to veterinary patients). The exclusion 
criteria included dogs with confounding ophthalmic 
or gastrointestinal disease. Dogs were also excluded if 
they had received dopamine agonists or antagonists or 
other medications with known antiemetic properties, 
including antihistamines and maropitant within 1 week 
before the start of the study. In addition, lactating and 
pregnant dogs were excluded.
Treatments
The investigational veterinary product used in this 
study was ropinirole 30 mg/mL ophthalmic solution 
in a single-use blow fill sealed ampoule. The placebo 
ophthalmic solution was identical in appearance, and 
contained the same excipients but no active ingredient. 
The dose of ropinirole was determined based on 
previous studies where doses of 0.9–5.5 mg/m2 were 
investigated (data on file, Orion Pharma). Based on the 
results of these studies, the target dose of 3.75 mg/m2 
was selected for the present clinical study.
The number of eye drops (1–8) administered was 
determined according to the dog’s body weight. The 
body weight ranges were defined to match the target 
dose of 3.75 mg/m2 (2.7–5.4 mg/m2) as closely as 
possible. Body surface area was calculated using the 
following formula: body surface area=10.1 × (body 
weight in kg)0.67/100.16 Doses were administered in both 
eyes at one administration time and doses larger than 4 
drops were divided in 2 and given 2 min apart from each 
other to ensure overflow did not occur.
Study assessments
The owners were requested to feed the dogs at home 
1 hour (±30 min) before the treatment visit. At the 
treatment visit, the dog’s eligibility for the study was 
confirmed. Each dog underwent a physical examination 
and blood and urine samples were taken for laboratory 
tests. The eligible dogs were randomised to receive 
either ropinirole or placebo at 3:1 ratio. Randomisation 
was conducted by an independent randomisation 
specialist using computer software before the study 
start. Completely randomised blocks of four dogs 
were stratified by centre. All owners and investigators 
were masked to treatment allocation. The owner 
administered the eye drops under the supervision 
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Table 1 Distribution of dogs by sex, age, weight and ASA class
Ropinirole
N=100
Placebo
N=32
Sex
  Female 51 (51%) 19 (59%)
  Male 49 (49%) 13 (41%)
Age
  Median 6 years 5 years
  Range 7 months–16 years 11 months–16 years
Weight
  Median 24 kg 21 kg
  Range 1.9–66 kg 3.8–44 kg
ASA class
  I 80 (80%) 26 (81%)
  II 20 (20%) 6 (19%)
ASA, American Society of Anesthesiologists Classification.
of the veterinarian. If the owner had only little or no 
experience of administering eye drops to dogs, they 
were given further instructions. Each dog was given 
the initial dose (of ropinirole or placebo) at 0 hour. If 
the dog did not vomit, an equal dose was given 20 min 
after the initial dose using the same ampoule. The dogs 
were followed in the clinic for 8±2 hours after dosing. 
The end-of-study visit took place 3–5 days after the 
treatment visit whereby the dogs were re-examined.
The dopamine antagonist, metoclopramide 0.5 mg/
kg subcutaneously, was administered as an antidote 
based on the judgement of the veterinarian if vomiting 
continued for more than 1 hour or if the vomiting was 
considered excessive.
Efficacy and usability of the product
The primary efficacy variable was induction of 
vomiting within 30 min following the initial treatment 
administration. A treatment success was recorded 
if vomiting occurred within 30 min of the initial 
administration regardless of whether the dog received 
a second dose at 20 min.
Other variables recorded were time to first vomit 
from administration, duration of vomiting (time from 
first vomit to last vomit), number of vomits and form 
of vomited material (foam, fluid or solid). The use of 
metoclopramide was also recorded. The usability of the 
product was assessed both by the owner (a four-point 
categorical scale: very easy, easy, somewhat difficult 
or very difficult) and the observing investigator who 
assessed the owner’s success in administering the eye 
drops (on a three-point categorical scale: successful, 
successful but with difficulties, or not successful).
Safety
Physical examination was performed before and 8 hours 
after dosing. Local tolerance of the eyes, cardiovascular 
status (by auscultation) and the presence of any other 
abnormal clinical signs were assessed before and 
30 min, 2 hours, 4 hours and 8 hours after dosing. 
Laboratory variables (haematology, clinical chemistry 
and urinalysis) were assessed before dosing. All safety 
assessments were repeated at the end of study visit. 
Adverse events were recorded throughout the study.
Local ocular tolerance assessment included 
conjunctival hyperaemia, conjunctival discharge, 
conjunctival swelling, protrusion of the third eyelid, 
blepharospasm and itching. Each of the variables was 
scored separately on a four-point scale (none, mild, 
moderate or severe).
Statistics
Sample size was estimated using statistical analysis 
simulations. Analysis of the primary variable was 
repeated using 10 000 randomly generated datasets 
from binomial distribution expecting an average 
success rate of 85%. With the sample size of 90 dogs in 
the ropinirole treatment group, the study objective was 
achieved approximately in 85% of 10 000 statistical 
analyses yielding a 95% CI above 70%. The total 
planned sample size was 120 dogs, of which 25% of the 
dogs received placebo and so the study was powered to 
determine whether the success rate was significantly 
greater than 70%.
The primary efficacy variable, induction of vomiting 
within 30 min, was analysed for the ropinirole group as 
a single proportion analysis using a generalised linear 
mixed model. The proportion of responders was treated 
as a binomial random variable and a logit link function 
was applied.
The treatment group was included as a fixed effect 
and the study centre as a random effect in the model. 
Data were analysed on an intention-to-treat (ITT) basis 
and the number of dogs deviating from the protocol is 
reported. The null hypothesis for the primary efficacy 
variable was that less than 70% of the dogs will vomit 
within 30 min.
Changes in heart rate were analysed using a repeated 
measures analysis of a covariance model. The statistical 
model included treatment, time and treatment–time 
interaction as fixed effects, the study centre as a random 
effect and the baseline value as a covariate. All other 
variables were evaluated descriptively.
Sample size estimation and statistical analyses were 
performed with SAS for Windows V.9.4 (SAS Institute, 
Cary, NC, USA).
Results
A total of 132 dogs were randomised, of which 100 dogs 
received ropinirole and 32 dogs received placebo. All 
randomised dogs (n=132) were included in the ITT and 
safety dataset.
The demographic and other baseline characteristics 
were comparable in the treatment groups (table 1). The 
age ranged from 7 months to 16 years, and the weight 
ranged from 1.9 to 66 kg. The dogs classified as ASA II 
had various types of diseases, the most common being 
heart murmur, arthritis and otitis externa.
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Figure 1 Time to first vomit from administration of ropinirole.
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Figure 2 Duration of vomiting from first to last vomit in dogs that received 
ropinirole.
A wide range of breeds were represented, 40 mixed 
breeds and 38 purebreds of which the most common 
included Labrador Retriever, Golden Retriever, Shih Tzu 
and American Pit Bull Terrier.
The median initial and total dose of ropinirole was 
3.8 (range: 2.8–5.4) mg/m2 and 3.9 (range: 2.8–9.6) 
mg/m2, respectively. The median total dose for the 13 
dogs which received a second dose was 6.9 (range: 
5.7–9.6) mg/m2. The number of ropinirole drops for the 
initial dose varied from 1 to 8 and for the second dose 
from 1 to 4.
Vomiting within 30 min
In all, 95 of the 100 dogs treated with ropinirole vomited 
within 30 min in the ITT population. The estimate of 
the responder rate in the statistical analysis was 97% 
(95% CI: 83% to 99%). Based on the a priori power 
calculation, the responder rate was significantly higher 
than 70% as the lower 95% confidence limit exceeded 
70% of the population.
The majority of dogs (87%) responded to the first 
dose of ropinirole, the second dose being needed in 
13% (13/100) of the dogs. Out of the 13 dogs, eight 
dogs vomited within 30 min after the initial dose. Two 
more dogs vomited within 37 min.
All of the five non-responders in the ropinirole 
group violated the protocol with a delay in receiving 
the second dose. Thus, in the per protocol population, 
in dogs without protocol violations, all dogs (100%) 
vomited within 30 min. None of the dogs in the placebo 
group vomited within 30 min.
Time to first vomit
Figure 1 shows the time to first vomit for ropinirole. Half 
of the dogs vomited within 10 min (range: 3–37 min). 
There was a tendency for dogs that received a dose 
above the target dose to start vomiting sooner than the 
dogs receiving a dose below the target dose.
Other vomiting-related variables
The median duration of vomiting for ropinirole was 
16 (range: 0–108) min. As shown in figure  2, for the 
majority (75%) of the dogs, the duration of vomiting 
was less than 30 min and in approximately 90% of the 
dogs the duration of vomiting was less than 45 min.
The median number of vomits for ropinirole was 4.0 
(range 1–13). The form of vomit expelled nearly always 
(89%) contained solid material. Metoclopramide was 
given to five dogs and none of these dogs vomited again 
after metoclopramide had been administered; these 
dogs are included in figure  2. There were three dogs 
for which the last vomit occurred at 66–108 min but 
the vomits were isolated incidents with long intervals 
and did not require metoclopramide based on the 
investigator’s judgement.
Usability of the product
All owners were able to administer the eye drops and 
96% of them assessed the administration to be very 
easy or easy (figure  3A). This was confirmed by the 
veterinarians’ assessment, which showed that 93% of 
the owners administered the eye drops successfully to 
their dog (figure 3B).
Safety
Local tolerance of the eyes to ropinirole was good. The 
most prevalent ocular signs in the ropinirole group were 
hyperaemia (51%), protrusion of the third eyelid (39%) 
and conjunctival discharge (35%), all of which were 
transient and mild or moderate. The same signs were 
present in the placebo group in 22%, 3% and 19% of 
the dogs, respectively. They were most evident at 30 min 
and were reduced at 2 hours and had almost completely 
abated by the examination performed 8 hours after the 
administration. Noteworthy is that ocular hyperaemia 
was reported in nearly 10% of the dogs prior to the 
treatment administration. Observations of the dogs 
during the treatment visit most commonly revealed 
lethargy (43%) and nausea (11%) in the ropinirole 
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Figure 3 Usability of the product: (a) ease of administration of eye drops as 
assessed by owners and (b) success to administer the eye drops by the owner as 
assessed by veterinarians.
group 30 min after treatment administration while 
these signs were not reported in the placebo group.
Transient increase in heart rate lasting approximately 
2 hours from dosing was noticed in the ropinirole 
group. After 30 min of administration of the product, 
the heart rate had increased by 14% (95% CI: 7% to 
20%) relative to baseline heart rate, whereas following 
placebo administration, the proportionate change in 
heart rate relative to baseline was −2% (95% CI: −11 to 
6%). In the ropinirole group, tachycardia was reported 
as an adverse event based on the investigator’s clinical 
judgement in five dogs (median of maximum heart rate 
was 180 bpm, range: 160–200 bpm), while no events 
were reported in the placebo group. Five dogs with 
cardiac murmur were recruited in the study, of which 
four received ropinirole and one received placebo. No 
cardiovascular safety issues were reported in these dogs 
during the study. No safety concerns were raised based 
on the laboratory safety variables.
Discussion
The primary efficacy endpoint of the present study was 
vomiting within 30 min regardless of whether a second 
dose was required. The results clearly demonstrate that 
ropinirole eye drops are effective in inducing vomiting 
in healthy dogs, as 95% of the dogs vomited within 30 
min of receiving ropinirole. Those dogs that did not 
respond within 30 min of the first dose did not follow 
the study protocol precisely in that there was some 
delay in administering the second dose. The present 
study clearly demonstrates that ropinirole has a fast 
onset of action because the median time to first vomit 
was 10 min, with a range of 3–37 min.
The sooner the dog evacuates the potentially 
poisonous contents of its stomach by vomiting, the lower 
the risk that the toxic substance will be absorbed. In 
cases of the most rapidly absorbed harmful substances, 
such as xylitol, induction of emesis is most effective 
within the first 30 min to 1 hour.17 Furthermore, the 
time needed for the gastric contents to move into the 
small intestine in the dog usually has a lag phase of 
about 40 min following eating but there is a wide range 
(15–108 min), and gastric emptying also depends, 
among other things, on the type of food eaten.18 Based 
on these published data, vomiting within 30 min was 
chosen as the primary efficacy endpoint in the present 
study as this would be effective in decontaminating 
dogs that have ingested harmful substances or material 
in the majority of cases.
The duration of vomiting period with ropinirole 
was short as half of the dogs vomited for less than 
10 min and in nearly all dogs vomiting ended 
spontaneously within 40 min. Metoclopramide, the 
protocol-specified antidote, was considered necessary 
in only five dogs, which can be regarded a very low 
portion.
The protocol provided the option of giving a second 
dose to those dogs that did not vomit within 20 min of 
the initial dose. This was required in only 13 of the dogs 
treated and 8 of these subsequently vomited within the 
30 min time limit. All ropinirole dogs that did not vomit 
within 30 min had some delay in the administration of 
this second dose suggesting that timely redosing may 
increase the efficacy of ropinirole as the delay in redosing 
seen in the ropinirole dogs could have explained the 
diminished effect. This leads to the conclusion that if 
a second dose is needed, it should preferably be given 
within 20 min after the initial dose to ensure maximal 
efficacy.
Overall, the product was well tolerated. Most 
reported side effects were mild or moderate and resolved 
quickly, within a few hours of treatment administration. 
Ropinirole solution proved to have good local eye 
tolerance. The signs in the eyes, associated most 
likely with ropinirole or the excipients, may indicate 
some ocular discomfort, which can be considered a 
disadvantage compared to parenteral administration 
of apomorphine. However, most of the signs in all dogs 
were completely resolved within 2 hours. They are 
suggestive of local activation of D2 receptors in the eye 
rather than a direct irritant effect because they resolved 
very quickly and have in previous studies resolved 
more rapidly when D2 receptor antagonists have been 
administered (data on file, Orion Pharma). Lethargy, 
which was the most commonly observed systemic 
sign, is considered in this context to be associated with 
nausea, which was another often reported finding that 
would be expected to be seen with any emetic as a 
prelude to vomiting in dogs.2 19
Transient tachycardia occurred in five dogs 
when treated with ropinirole, possibly also due to 
the pharmacological effect on dopamine receptors. 
However, vomiting itself may physiologically cause 
an increase in heart rate due to changes in autonomic 
discharge that accompany the vomiting response.19 
The number of dogs included in the present study with 
subclinical cardiac disease (detected by the presence 
of a heart murmur) was very low (only four in the 
ropinirole-treated group). However, none of these dogs 
showed adverse cardiac effects following ropinirole 
administration. It seems likely that short-term 
tachycardia caused by this drug is of little consequence 
to dogs with subclinical cardiac disease.
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The usability of ropinirole eye drops was excellent 
as all owners were able to administer the product and 
nearly all assessed the administration to be easy or very 
easy. Furthermore, it is reassuring that the veterinarians 
assessed all owners as being able to administer the 
drug. An important aspect of this treatment is that in 
situations when the dog has ingested toxic material, the 
eye drop dosage form could enable owners to administer 
the drug to their dogs. This way valuable time would 
not be lost during the journey to the veterinary practice. 
In such emergency situations, administering the 
prescription product to an asymptomatic dog at home 
under the direction of a veterinarian, provided that no 
contraindications for vomiting induction are present, 
would expedite the decontamination process and could 
even save the dog’s life.
There are some limitations of the present study. 
First, evacuation of the stomach was not measured 
quantitatively as the amount and form of vomit 
were assessed visually. Nevertheless, the number of 
vomiting events (median 4.0) is considered sufficient to 
have achieved the goal of evacuation of the stomach. 
In addition, the form of vomit expelled nearly always 
contained solid material that the dog had eaten before 
the treatment, which supports the fact that ropinirole 
induces vomiting that empties the stomach contents. 
Second, the study did not assess the effects of ropinirole 
in dogs that had ingested something harmful. This 
study was undertaken to assess the effect of ropinirole, 
when administered as eye drops by dog owners, on 
inducing a vomiting response in a large population 
of healthy dogs. The wide range of ages, weights and 
breeds of dogs included in the study means that the 
dogs can be considered representative of the target 
population. It would not have been ethical to run a 
blinded placebo controlled study involving dogs that 
had potentially been poisoned. Third, cardiovascular 
parameters measured were limited to heart rate taken by 
auscultation. Electrocardiography and blood pressure 
have been examined prior to this study in standalone 
cardiovascular safety studies involving laboratory dogs 
with no major findings, except transient increase in heart 
rate (data on file, Orion Pharma). Therefore, this study 
conducted by general practitioners was performed using 
the standard clinical heart rate assessment suitable to 
monitor the expected cardiovascular findings.
In conclusion, ropinirole, administered topically to 
the eye by the owner, is effective and safe in inducing 
vomiting in dogs with the target dose 3.75 mg/m2 
(range: 2.8–5.4 mg/m2). The product has a fast onset of 
action, and the dose can be repeated within 20 min after 
the administration of the initial dose if the dog does not 
start vomiting before that. It is well tolerated with only 
minor and transient local discomfort to the eyes and 
mild, short-term tachycardia seen in a small proportion 
of dogs. The formulation developed proved highly 
practical for owners to administer successfully, despite 
their lack of experience in giving ocular medications. 
The results of this clinical study show that ropinirole 
eye drops are easy to use, effective and safe in inducing 
vomiting with a fast onset of action and a spontaneous 
recovery in dogs.
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